🔗 Share this article

As America proceeds with sweeping changes to its immunization guidelines, one figure has emerged somewhat surprisingly: Høeg, a Danish American sports physician and epidemiologist who rose to prominence by casting doubt on coronavirus vaccines in the global health crisis and has focused upon alleged fatalities following COVID-19 vaccination in her short position at the FDA.

Proposed Shifts to Pediatric Vaccine Program

Agency leaders had intended to announce radical revisions to the pediatric immunization program recently, bringing the US with the Danish immunization schedule, sources say – a major change that would put the US at odds with many the international standard with little proof for benefit. The planned update has been pushed back until the new year.

In place of the director of the vaccine center, Høeg is listed to present at the gathering. She was recently named acting director of the FDA’s drug evaluation center, the fifth individual to run the office this year.

A New Direction at the Agency

Høeg's temporary position may indicate a closer partnership between the pharmaceutical and vaccine divisions as Dr. Høeg and Prasad consolidate power at the FDA – and it signals a greater focus upon dismantling long-standing immunizations at the FDA.

Dr. Høeg has repeatedly called for halting certain childhood vaccine recommendations in the US in order to be more like the Danish model, a country with comprehensive healthcare and a citizenry about the population of the state of Wisconsin.

To date statements, she has persisted in emphasizing on vaccines – typically the responsibility of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Concerns Over Qualifications

The appointee has little discernible background in pharmaceutical research, regulation or management, which has been typical for previous heads of the CBER. She has served at the FDA as a top consultant to the agency head and the vaccine center since spring.

“She doesn’t seem to have the necessary background” for leading the drug-regulation department, said a neurologist and psychiatrist. “She lacks experience running a clinical trial. She lacks experience in running a major agency. She is not an expert in pharmaceutical oversight.”

Past directors of the center would “understand laws and regulations and the science of drug development”, said Dr. Janet Woodcock. “Objectively, she has not acquired the sort of resume that former directors who headed CBER have had.”

This division has an enormous range of responsibilities at the agency, the former commissioner emphasized.

“The public just pays attention on the innovative therapies, but the generic program clears a multitude of off-brand pharmaceuticals. There is also a biologic copycat branch, OTC medication office and other areas, and each of these must be managed,” Dr. Woodcock said. “The responsibility you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a major administrative component to the role, which manages more than 5,000 personnel. “It’s a enormous administrative position, if you execute it properly,” she added.

Response and Disputed Programs

In response to concerns about Høeg’s qualifications and whether this assignment indicates more teamwork among agency officials on vaccines, a spokesperson responded that the “questions stem from incorrect premises”.

“Her experience matches the duties of her role,” the representative said, pointing to the months Dr. Høeg spent advising the FDA commissioner on “drug safety and approval science, including computational safety modeling and immunization monitoring”.

In her interim role, Høeg inherits the commissioner’s controversial priority voucher program, a controversial expedited medication authorization process that apparently worried her former heads. “By what process are these therapies being selected for this fast-track system? Who takes the calls?” Dr. Howard asked. “There is a lot of confidentiality happening at the FDA right now.”

Broadly speaking, he stated, “the Food and Drug Administration looks to be trending towards more relaxed oversight of most medications, except for immunizations.”

Established Past Work on Immunizations

Regarding vaccines, Dr. Høeg has a more established, if troubling, history, some experts observe. She authored a research paper using non-validated public submissions to determine the incidence of heart inflammation after Covid vaccination. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who reportedly have modified findings to imply Covid vaccinations are more dangerous than they are.

Among her “wish list” for the current federal leadership included changing rules for recently developed shots and halting “unnecessary” immunizations, she stated following the vote on a podcast. At the agency, Høeg has according to sources proposed preventing teenage boys from receiving COVID-19 vaccines.

“She’s an all-around true believer who commences with her conclusions and reverse-engineers to retrofit the evidence in a highly disingenuous, fraudulent fashion,” Howard said.

Taking Control and a “Campaign of Retribution”

Dr. Høeg joined other contrarians, {like|